Medicare AdvantagePrior AuthMedium impact
Trudhesa (dihydroergotamine mesylate) (Revised)
Humana·Neurology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Trudhesa nasal spray (dihydroergotamine mesylate) for acute migraine treatment, effective January 1, 2025. Patients must have tried and failed Ubrelvy plus one other specified migraine medication (naproxen, naratriptan, rizatriptan, or sumatriptan) before approval.
Action Required
Immediately: Update prior authorization procedures for Trudhesa nasal spray prescriptions for Humana Medicare Advantage patients. Ensure providers document previous treatment failure with Ubrelvy and at least one of these medications: naproxen, naratriptan, rizatriptan, or sumatriptan. Add prior auth reminder to neurology and primary care encounter forms. Claims will require pre-approval before dispensing.